Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS • Currently up 0.23 (+0.64%) in today's trading session

1 member of Congress has disclosed 4 trades in Agios Pharmaceuticals, Inc. (AGIO) via STOCK Act filings. The most recent disclosure was a purchase by Gilbert Cisneros on 3 March 2026. Aggregate disclosed activity totals roughly $32K in purchases (midpoint estimates from bracketed disclosure amounts).

Agios Pharmaceuticals, Inc. is currently trading at $36.28, positioned at 59% of its 52-week range ($22.24 – $46.00).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Copy PortfolioClaim Free Asset
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$36.28
24h Change
+0.23 (+0.64%)
52 Week Range
$22.24—$46.00
View on NASDAQ

Agios Pharmaceuticals, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for AGIO

Select to highlight on chart
4 transactions
Compliance: 100%
Gilbert Cisneros3 Mar 20267 Apr 2026PurchaseStock$1,001 - $15,000+24.25%
Gilbert Cisneros11 Dec 202512 Jan 2026PurchaseStock$1,001 - $15,000+29.57%
Gilbert Cisneros17 Apr 20256 May 2025PurchaseStock$1,001 - $15,000N/A
Gilbert Cisneros29 Jan 202511 Feb 2025PurchaseStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$2.16B

Volume

761.94K

Beta

0.54

P/E Ratio

-5.00

Fundamentals

EPS

$-7.25

Div. Yield

—

Open

$35.59

Day Range

$35.59 — $36.68

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Brian Goff
IPO Date
2013-07-24
Website
www.agios.com

Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a med...

Earnings

Next Report

Q2 2026

30 Jul

EPS Est.

$-1.66

Rev. Est.

$26.1M

Days Until

7

Recent Quarters

Q1 202629 Apr
EPS$-1.69
Beat 6.6%
Q4 202512 Feb
EPS$-1.85
Beat 6.1%
Q3 202530 Oct
EPS$-1.78
Beat 7.8%
Q2 202531 Jul
EPS$-1.93
Miss 10.9%
Q1 20251 May
EPS$-1.55
Beat 13.9%
Q4 202413 Feb
EPS$-1.74
Miss 3.0%
Q3 202431 Oct
EPS$4.20
Miss 74.8%
Q2 20241 Aug
EPS$-1.69
Miss 7.0%
Q1 20242 May
EPS$-1.45
Beat 11.6%
Q4 202315 Feb
EPS$-1.72
Miss 4.9%
Q3 20232 Nov
EPS$-1.64
Beat 3.0%
Q2 20233 Aug
EPS$-1.51
Beat 5.6%
Q1 20234 May
EPS$-1.47
Beat 14.5%
Q4 202223 Feb
EPS$0.67
Beat 142.1%
Q3 20223 Nov
EPS$-1.49
Beat 14.9%
Q2 20224 Aug
EPS$-1.68
Beat 5.6%
Q1 20225 May
EPS$-1.74
Beat 6.0%
Q4 202124 Feb
EPS$-1.81
Miss 5.8%
Q3 20213 Nov
EPS$-1.48
Beat 8.1%
Q2 202129 Jul
EPS$-1.36
Beat 2.2%
Q1 202129 Apr
EPS$-1.31
Miss 6.5%
Q4 202025 Feb
EPS$-1.41
Beat 0.0%
Q3 20205 Nov
EPS$-1.43
Miss 2.1%
Q2 202030 Jul
EPS$-1.31
Beat 7.8%
Q1 202030 Apr
EPS$-0.59
Beat 65.3%
Q4 201913 Feb
EPS$-1.60
Beat 10.1%
Q3 201931 Oct
EPS$-1.81
Beat 2.2%
Q2 20191 Aug
EPS$-1.87
Miss 8.1%
Q1 20192 May
EPS$-1.59
Beat 8.6%
Q4 201814 Feb
EPS$-1.58
Beat 4.2%
Q3 20181 Nov
EPS$-1.63
Beat 3.5%
Q2 20182 Aug
EPS$-1.19
Beat 26.5%
Q1 20184 May
EPS$-1.63
Miss 1.9%
Q4 201714 Feb
EPS$-1.81
Miss 9.7%
Q3 20171 Nov
EPS$-1.59
Beat 8.6%
Q2 20178 Aug
EPS$-1.78
Miss 17.1%
Q1 20174 May
EPS$-1.56
Beat 12.8%
Q4 201616 Feb
EPS$-1.34
Beat 13.6%
Q3 20163 Nov
EPS$-1.63
Miss 8.0%
Q2 20164 Aug
EPS$-1.47
Miss 14.8%
Q1 20165 May
EPS$-0.61
Beat 11.6%
Q4 201518 Feb
EPS$-1.08
Miss 300.0%
Q3 20155 Nov
EPS$-1.07
Miss 20.2%
Q2 20156 Aug
EPS$-0.85
Miss 63.5%
Q1 20157 May
EPS$-0.13
Beat 84.9%
Q4 201417 Feb
EPS$-0.76
Miss 38.2%
Q3 20147 Nov
EPS$0.10
Beat 119.2%
Q2 20147 Aug
EPS$-0.54
Miss 14.9%
Q1 20148 May
EPS$-0.39
Miss 5.4%
Q4 20136 Mar
EPS$-0.40
Miss 17.6%
Q3 20137 Nov
EPS$-0.47
Miss 67.9%
Q2 20135 Sept
EPS$-0.29
Q2 20135 Sept
EPS$-2.80
Miss 775.0%
Q3 201231 Dec
EPS$-0.23
Q2 201230 Sept
EPS$-0.20
Q1 201230 Jun
EPS$-0.24
Q4 201131 Mar
EPS$-0.20

2 politicians traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

AAPL

Apple Inc.

22
$321.66-4.23 (-1.30%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

WBI

WaterBridge Infrastructure LLC

17
$35.54-0.67 (-1.85%)
Energy
Held by same politician
1 politician
View Stock

SPY

State Street SPDR S&P 500 ETF Trust

17
$738.18-9.23 (-1.23%)
Financial Services
Held by same politician
1 politician
View Stock

Frequently Asked Questions about AGIO

Which members of Congress have traded AGIO?
1 member of Congress has disclosed 4 trade in Agios Pharmaceuticals, Inc. (AGIO) under the STOCK Act: Gilbert Cisneros.
When was AGIO most recently disclosed by Congress?
The most recent AGIO disclosure was a purchase by Gilbert Cisneros on 3 March 2026.
What is the total disclosed congressional trading volume for AGIO?
Members of Congress have disclosed approximately $32K in AGIO purchases (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in AGIO?
This AGIO page updates as soon as new STOCK Act disclosures are filed for Agios Pharmaceuticals, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
Follow on XJoin our Discord
PoliticiansBillsPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.